Organobalance to Present Latest Findings in Bacteria Research

01 Feb 2017 --- Researchers from Organobalance are set to present preliminary results of research looking into microorganisms for their beneficial effects to be further used in the feed, health care, and pharmaceutical industries. The results will be announced during the international PROBIOTA convention, which will take place for the first time in Berlin on 1-3 February.

One year ago, the German Federal Ministry of Education and Research (BMBF) approved funding to Organobalance for the research project, Good Bacteria, and Bioactives in Industry (GOBI), which has Evonik Nutrition & Care GmbH and Bionorica SE as partners.

The international PROBIOTA convention is recognized as one of the leading conferences for the probiotics-focused food and pharma industries and on the impact of bacteria on human and animal health.

Based on laboratory findings with lactic acid bacteria, Organobalance will present the latest scientific evidence of the importance of beneficial bacteria for intestinal health.

The lactic acid bacteria were taken from the company’s own collection of several thousand strains.

“We want to study the positive impact of healthy bacteria, and showcase some of the resulting alternatives for promoting human well-being,” emphasized CEO Prof. Dr. Christine Lang prior to PROBIOTA.

“In recent years, we had seen a tremendous increase in the research into the interactions between microorganisms and humans or animals. Some important insights have already been made.”

“Based on these, we are now able to create a new generation of alternative biological agents to be used for a healthy nutrition,” Ms. Lang continued.

The GOBI research project is scheduled to run for a total of six years. This is the first time that interim results are presented.